TABLE 1.
Transplant biopsy specimens: PTCL groups C (1–3) and PTCL Subgroup C3 in histologic categoriesa
| Group C (1–3) |
Subgroup C3 |
|||
|---|---|---|---|---|
| Histologic Findings | n | C in total n, % | C3/C (1–3) | Subgroup C3 in group C (1–3), % |
| Tubulointerstitial rejectiona (n=70) | 38 | 54b | 24/38 | 63b |
| Transplant endarteritisa (n=8) | 3 | 38b | 2/3 | 67 |
| Transplant glomerulitisa (n=16) | 12 | 75b | 7/12 | 58b |
| All transplant glomerulopathya (n=50) | 32 | 64 | 24/32 | 75 |
| Global (n=38) | 29 | 76b | 22/29 | 76b |
| Segmental (n=12) | 3 | 25 | 2/3 | 67 |
| All transplant sclerosing vasculopathya (n=45) | 30 | 67b | 18/30 | 60b |
| Active with endarteritis (n=22) | 16 | 73b | 12/16 | 75b |
| Inactive without endarteritis (n=23) | 14 | 61b | 6/14 | 43b |
| Calcineurin inhibitor toxicity (n=11) | 4 | 36b | 2/4 | 50 (NS) |
| All comparative transplant control group (n=64) | 3 | 5 | 1/3 | 33 |
| Others (n=48) | 1 | 2 | 0/1 | 0 |
| Recurrence/de novo diseases (n=11) | 0 | 0 | 0/0 | 0 |
| Diabetes mellitus (n=5) | 2 | 40 | 1/2 | 50 |
| All C4d+a (n=56) | 34 | 61b | 28/34 | 82b |
| C4d+ diffuse (n=40) | 27 | 68b | 23/27 | 85b |
| C4d+ focal (n=16) | 7 | 44b | 5/7 | 71b |
| All C4d−a (n=127) | 31 | 24 | 13/31 | 41 |
| All biopsies ≤1 yra (n=38) | 2 | 5 | 0/2 | 0 |
| Tubulointerstitial rejection (n=8) | 0 | 0 | 0/0 | 0 |
| Transplant endarteritis without (n=2) | 0 | 0 | 0/0 | 0 |
| Transplant glomerulitis (n=l) | 0 | 0 | 0/0 | 0 |
| Transplant glomerulopathy (n=2) | 0 | 0 | 0/0 | 0 |
| Transplant sclerosing vasculopathy (n=3) | 1 | 33 | 0/1 | 0 |
| All C4d+ (n=9) | 0 | 0 | 0/0 | 0 |
| C4d+ diffuse (n=5) | 0 | 0 | 0/0 | 0 |
| C4d+ focal (n=4) | 0 | 0 | 0/0 | 0 |
| All C4d−(n=29) | 2 | 7 | 0/2 | 0 |
| All biopsies >1 yra (n=145) | 63 | 43 | 41/63 | 65 |
| Tubulointerstitial rejection (n=62) | 38 | 61 | 24/38 | 63 |
| Transplant endarteritis (n=6) | 3 | 50 | 2/3 | 67 |
| Transplant glomerulitis (n=15) | 12 | 80 | 7/12 | 58 |
| Transplant glomerulopathy (n=48) | 32 | 67 | 24/32 | 75 |
| Transplant sclerosing vasculopathy (n=42) | 29 | 69 | 18/29 | 62 |
| All C4d+ (n=47) | 34 | 72 | 28/34 | 82 |
| C4d+ diffuse (n=35) | 27 | 77 | 23/27 | 85 |
| C4d+ focal (n=12) | 7 | 58 | 5/7 | 71 |
| All C4d− (n=98) | 29 | 30 | 15/29 | 52 |
a
Cases can show more than one rejection-associated histologic change.
b
Comparison of PTCL-C1–3 and PTCL Subgroup C3 with transplant control group, P<0.05.
Specimens in the “comparative control group” and in the “calcineurin inhibitor toxic group” lack per definition any evidence of rejection or C4d positivity. No analysis performed in some groups because of either overlap with cases in control category or small case numbers.
PTCL, peritubular capillary basement membrane multilamination; NS, not significant.